Experienced in Choroid Plexus Carcinoma

Dr. Rakesh Gaur

Hematology Oncology | Hematology | Oncology

Shawnee Mission Medical Center Inc

9301 W 74th St, 100 Ahmg Hematology Oncolo,

Merriam, KS

Clinical Trials:Currently Recruiting for 4 Trials

Accepting New Patients

Offers Telehealth

Experienced in Choroid Plexus Carcinoma

Shawnee Mission Medical Center Inc

9301 W 74th St, 100 Ahmg Hematology Oncolo,

Merriam, KS

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rakesh Gaur is a Hematologist Oncology specialist and a Hematologist in Merriam, Kansas. Dr. Gaur is rated as an Experienced provider by MediFind in the treatment of Choroid Plexus Carcinoma. His top areas of expertise are Colorectal Cancer, Lung Cancer, Myelodysplastic Syndrome (MDS), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Gaur is currently accepting new patients.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 86 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Hematology

Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Adventhealth Shawnee Mission

Adventhealth South Overland Park, Inc

Adventhealth Ottawa

Languages Spoken

English

Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

Cigna

Cox Health

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Home State Health

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Oscar

Sunflower Health Plan

HMO
MANAGED MEDICAID PLAN

TeamCare

OTHER COMMERCIAL

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 11 Less Insurance Carriers -

Locations

SHAWNEE MISSION MEDICAL CENTER INC
9301 W 74th St, 100 Ahmg Hematology Oncolo, Merriam, KS 66204

Call: 913-632-9100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

86 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab, Sargramostim

Study Phase: Phase 2/Phase 3

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Enrollment Status: Recruiting

Publish Date: October 08, 2025

Intervention Type: Drug

Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib

Study Phase: Phase 2

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

Enrollment Status: Recruiting

Publish Date: May 04, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Bupropion Hydrochloride Controlled-Release

Study Phase: Phase 3

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer

Enrollment Status: Recruiting

Publish Date: April 06, 2025

Intervention Type: Other

Study Phase: Not Applicable

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Biological, Radiation

Study Drug: Pembrolizumab

Study Phase: Phase 2

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma

Enrollment Status: Completed

Publish Date: October 08, 2025

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride

Study Phase: Phase 3

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)

Enrollment Status: Active_not_recruiting

Publish Date: October 03, 2025

Intervention Type: Other, Radiation

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: October 01, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 30, 2025

Intervention Type: Radiation

Study Phase: Phase 3

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 26, 2025

Intervention Type: Drug, Biological, Procedure

Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate

Study Phase: Phase 2

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Enrollment Status: Active_not_recruiting

Publish Date: September 26, 2025

Intervention Type: Drug, Procedure, Biological

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 2

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate

Study Phase: Phase 2

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Cabozantinib, Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy

Study Phase: Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Lenalidomide

Study Phase: Phase 3

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Biological

Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b

Study Phase: Phase 3

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Afatinib Dimaleate, Cetuximab

Study Phase: Phase 2/Phase 3

A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)

Enrollment Status: Active_not_recruiting

Publish Date: September 17, 2025

Intervention Type: Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 2

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 16, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 3

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis

Enrollment Status: Completed

Publish Date: September 09, 2025

Intervention Type: Other, Biological

Study Drug: Isatuximab

Study Phase: Phase 2

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone

Study Phase: Phase 2

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Drug

Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide

Study Phase: Phase 3

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Drug, Radiation, Procedure

Study Drugs: Doxorubicin, Ifosfamide, Pazopanib

Study Phase: Phase 2/Phase 3

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Enrollment Status: Active_not_recruiting

Publish Date: July 30, 2025

Intervention Type: Other, Drug

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2/Phase 3

The National Myelodysplastic Syndromes Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: July 02, 2025

Intervention Type: Other

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

Enrollment Status: Active_not_recruiting

Publish Date: June 10, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Bortezomib, Dexamethasone, Elotuzumab, Lenalidomide

Study Phase: Phase 1/Phase 2

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 21, 2025

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Completed

Publish Date: May 21, 2025

Intervention Type: Drug

Study Drug: Rucaparib

Study Phase: Phase 2

Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases

Enrollment Status: Completed

Publish Date: May 16, 2025

Intervention Type: Other, Drug

Study Drugs: Cisplatin, Veliparib

Study Phase: Phase 2

Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)

Enrollment Status: Active_not_recruiting

Publish Date: April 08, 2025

Intervention Type: Drug, Biological

Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide

Study Phase: Phase 2

Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Enrollment Status: Completed

Publish Date: April 06, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Enrollment Status: Active_not_recruiting

Publish Date: March 30, 2025

Intervention Type: Drug

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 19, 2025

Intervention Type: Drug

Study Drugs: TAK-700, Bicalutamide

Study Phase: Phase 3

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Enrollment Status: Active_not_recruiting

Publish Date: February 18, 2025

Intervention Type: Other, Drug

Study Drugs: Vemurafenib, Cobimetinib

Study Phase: Phase 2

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Drug

Study Drugs: Efatutazone, Paclitaxel

Study Phase: Phase 2

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)

Enrollment Status: Terminated

Publish Date: January 24, 2025

Intervention Type: Biological, Drug

Study Drugs: HSPPC-96, Bevacizumab

Study Phase: Phase 2

A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial

Enrollment Status: Completed

Publish Date: January 16, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab

Study Phase: Phase 2/Phase 3

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2025

Intervention Type: Device, Biological, Other, Drug

Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab

Study Phase: Phase 2

View 46 Less Clinical Trials

21 Total Publications

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).

Journal: Cancer

Published: March 11, 2021

View All 21 Publications

Similar Doctors

Experienced in Choroid Plexus Carcinoma

Dr. David E. Einspahr

Hematology Oncology | Hematology | Oncology

Experienced in Choroid Plexus Carcinoma

Dr. David E. Einspahr

Hematology Oncology | Hematology | Oncology

1500 SW 10th Ave,

Topeka, KS

(53.9 miles away)

785-354-6000

Languages Spoken:

English

See accepted insurances

Accepting New Patients

David Einspahr is a Hematologist Oncology specialist and a Hematologist in Topeka, Kansas. Dr. Einspahr is rated as a Distinguished provider by MediFind in the treatment of Choroid Plexus Carcinoma. His top areas of expertise are Lung Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Einspahr is currently accepting new patients.

Experienced in Choroid Plexus Carcinoma

Dr. Marc S. Hoffmann

Hematology Oncology | Hematology | Oncology

Experienced in Choroid Plexus Carcinoma

Dr. Marc S. Hoffmann

Hematology Oncology | Hematology | Oncology

Select Physical Therapy Holdings Inc

2301 S Missouri 291 Hwy,

Independence, MO

(17.9 miles away)

816-373-9328

Languages Spoken:

English, French, Spanish

See accepted insurances

Accepting New Patients

Offers Telehealth

Marc Hoffmann is a Hematologist Oncology specialist and a Hematologist in Independence, Missouri. Dr. Hoffmann is rated as a Distinguished provider by MediFind in the treatment of Choroid Plexus Carcinoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration. Dr. Hoffmann is currently accepting new patients.

VIEW MORE CHOROID PLEXUS CARCINOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gaur's expertise for a condition

ConditionClose